To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Ziehl-Abegg moved to Forsyth ...
Editor's note: An earlier version of this story included an incorrect graphic noting only two Anheuser-Busch beers in the 2025 Ad Meter top 10. In fact, there were four: one each from Budweiser, Bud ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Despite the risk of AI singularity resulting in human ...
Hopefully most American families managed to avoid politics during their Thanksgiving gathering. But for investors, political fallout is not so easy to eschew. And going into 2026, markets face the ...
Wall Street closed mostly lower as markets had a difficult time finding clear direction on Wednesday as traders and investors assessed the latest labor data. From a sector vantage point, three of the ...
Cutting corners: The jet engine – once a symbol of speed and flight – is finding new life on the ground, fueling the world's artificial intelligence infrastructure. Faced with long delays in ...
Digital asset treasury companies such as Tom Lee’s BitMine have contributed to the increase in the entry queue, but the network’s Petcra upgrade may have also helped. Ethereum’s staking queue has ...
The rise of AI and quantum computing has fueled demand for data center capacity. Revenue and income from operations are growing steadily. Growth has slowed in recent years, but rising demand and ...
As Eli Lilly (NYSE: LLY) and Novo Nordisk (Nasdaq Copenhagen: NOVO-B) scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, a much smaller potential rival ...
Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...
Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...
With the current state of the economy due to inflation, high-interest rates, potential AI disruptions, and a weakening labor market, it's quite refreshing to own dividend stocks. Particularly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results